Clinical Report: Interstitial Photodynamic Therapy for Head and Neck Cancer

Overview

This report discusses a Phase 1/2 clinical study evaluating the safety and efficacy of porfimer sodium (Photofrin®) mediated interstitial photodynamic therapy (I-PDT) for patients with locally advanced or recurrent head and neck cancer. The study targets patients who have not responded to standard therapies and are not candidates for curative treatment.

Background

Locally advanced and recurrent head and neck cancers pose significant treatment challenges, often leading to poor outcomes with standard therapies. Photodynamic therapy (PDT) has emerged as a potential adjunctive treatment, utilizing a photosensitizing agent and light to target cancer cells. The ongoing clinical trial aims to assess the viability of I-PDT in this patient population, which is currently underserved by conventional treatment options.

Data Highlights

No numerical data available in the source material.

Key Findings

• The Phase 1/2 trial (NCT03727061) is evaluating I-PDT using porfimer sodium in patients with advanced or recurrent head and neck cancer.
• Patients enrolled in the trial have failed to respond to standard therapies and are not candidates for curative treatment.
• The study aims to define safety and recommended light-dose parameters for future phases.
• Photodynamic therapy has shown potential for local control and functional preservation in select cases.
• Current guidelines do not position PDT as a standard treatment option for recurrent or metastatic head and neck cancers.

Clinical Implications

Healthcare professionals should consider the investigational status of I-PDT when discussing treatment options with patients who have advanced or recurrent head and neck cancer. Participation in clinical trials may provide access to novel therapies that could improve patient outcomes.

Conclusion

The ongoing study of I-PDT represents a promising avenue for patients with limited treatment options in advanced head and neck cancer. Continued research is essential to establish its role in clinical practice.

References

1. Gal Shafirstein, Roswell Park Comprehensive Cancer Center, 2023 -- Interstitial Photodynamic Therapy for Head and Neck Cancer
2. NCCN GUIDELINES® INSIGHTS, 2023 -- Head and Neck Cancers
3. The ASCO Post — SIDEBAR: Photodynamic Therapy for Cancer
4. roswell park comprehensive cancer center — New Phase I/II Trial Using Multimodal PDT for Advanced, Recurrent Colorectal Cancer
5. the asco post — Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer
6. Journal of Gastroenterology — Long-term Results of Photodynamic Therapy for Local Recurrence Following Chemoradiotherapy or Radiotherapy in Esophageal Cancer
7. Photodynamic Therapy for Cancer
8. Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer
9. CE NCCN GUIDELINES® INSIGHTS Head and Neck Cancers
10. Study Details | NCT03727061 | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer | ClinicalTrials.gov
11. Guide to PHOTOFRIN® (porfimer sodium) / PDT Reimbursement